Incidence of hydromorphone-induced neuroexcitation in hospice patients

Journal of Palliative Medicine

Volumn 16, Issue 10, 2013, Pages 1205-1209

  Kullgren, Justin ^a,b   Le, Vy ^b   Wheeler, Warren ^b  

^a South College School of Pharmacy   (United States)

^b Nathan Adelson Hospice   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HYDROMORPHONE;

AGED; ALLODYNIA; ANALGESIA; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; FEMALE; HOSPICE PATIENT; HUMAN; HYDROMORPHONE INDUCED NEUROEXCITATION; HYPERALGESIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MYOCLONUS; PROSPECTIVE STUDY; SEIZURE;

AGED; ANALGESICS, OPIOID; FEMALE; GLUCURONATES; HOSPICE CARE; HUMANS; HYDROMORPHONE; INCIDENCE; KIDNEY FUNCTION TESTS; MALE; NEUROTOXICITY SYNDROMES; NEVADA; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84885701924     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2012.0467     Document Type: Article

References (30)

1. Hagen N, Swanson: Strychnine-like multifocal myoclonus and seizures in extremely high dose opioid administration: Treatment strategies. J Pain Symptom Manage 1997;14: 51-8.
2. Sjogren P, Jonsson T, Jensen NH, et al.: Hyperalgesia and myoclonus in terminal cancer patients treated with intravenous morphine. Pain 1993;55:93-97.
3. Thwaites D, McCann S, Broderick P: Hydromorphone neuroexcitation. J Palliat Med 2004;7:545-550.
4. Paramanandam G, Prommer E, Schwenke DC: Adverse effects in hospice patients with chronic kidney disease receiving hydromorphone. J Palliat Med 2011;14:1029-1033.
5. Osborne R, Joel S, Grebenik K, et al.: The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther 1993;54:158-167.
6. Wolff J, Bigler D, Christensen CB, et al: Influence of renal failure on the elimination of morphine and morphine glucuronides. Eur J Clin Pharmacol 1988;34:353-357.
7. Chauvin M, Sandouk P, Scherrmann JM, et al.: Morphine pharmacokinetics in renal failure. Anesthesiology 1987;66: 327-331.
8. Dean M: Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004;28:497-504.
9. Smith HS: Opioid metabolism. Mayo Clin Proc 2009;84:613-624.
10. Murray A, Hagen N: Hydromorphone. J Pain Symptom Manage 2005;29:S57-S66.
11. Smith MT: Neuroexcitatory effects of morphine and hydromorphone: Evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000;27:524-528.
12. Wright AW, Mather LE, Smith MT: Hydromorphone-3-glucuronide: A more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 2001;69:409-420.
13. Wright AW, Nocente ML, Smith MT: Hydromorphone-3-glucuronide: Biochemical synthesis and preliminary pharmacological evaluation. Life Sci 1998;63;401-411.
14. Lee M, Leng M, Tiernan E: Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med 2001;15:26-34.
15. Gardell LR, King T, Ossipov MH, et al: Opioid receptormediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. Neurosci Lett 2006;396:44-49.
16. Chu LF, Angst MS, Clark D: Opioid induced hyperalgesia in humans molecular mechanisms and clinical considerations. Clin J Pain 2008;24:479-496.
17. Babul N, Darke AC, Hagen N: Hydromorphone metabolite accumulation in renal failure [letter]. J Pain Symp Manage 1995;10:184-186.
18. Christrup L: Morphine metabolites. Acta Anaesthesiol Scand 1997;41:116-122.
19. Anderson G, Christup L, Sjogren P: Relationships among morphine metabolism, pain and side effects during longterm treatment: An update. J Pain Symptom Manage 2003;25:74-91.
20. Davison S, Mayo P: Pain management in chronic kidney disease: The pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3- glucuronide in hemodialysis patients. J Opioid Manag 2008;4:335-344.
21. Babul N, Darke AC: Putative role of hydromorphone metabolites in myoclonus. Pain 1992;51:260-261.
22. Sjogren P, Jonsson T, Jensen NH, et al.: Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other agonists. Pain 1994:59:313-316.
23. Vigano A, Fan D, Bruera E: Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain 1996;67:115-119.
24. De Stoutz N, Bruera E, Suarez-Almazor M: Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995;10:378-384.
25. Cherny N, Ripamonti C, Pereira J, et al.: Strategies to manage the adverse effects of oral morphine: An evidence-based report. J Clin Oncol 2001;19:2542-2554.
26. Sjogren P, Thunedborg LP, Christrup L, et al.: Is the development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories. Acta Anaesthesiol Scand 1998;42; 1070-1075.
27. Mercadante S: Pathophysiology and treatment of opioidrelated myoclonus in cancer patients. Pain 1998;5-9.
28. Bruera E, Franco J, Maltoni M, et al.: Changing pattern of agitated impaired mental status in patients with advanced cancer: Association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage 1995;10:287-291.
29. Massie MJ, Holland J, Glass E: Delirium in terminally ill cancer patients. Am J Psychiatry 1983;140:1048-1050.
30. McCann S, Yaksh T, von Gunten C: Correlation between myoclonus and the 3-glucuronide metabolites in patients treated with morphine or hydromorphone: A pilot study. J Opioid Manage 2010;6:87-94.